NFL Biosciences H1 2026 Net Loss Narrows 15% to EUR 1.53 Million
Bitget2026/10/22 16:10- NFL Biosciences’ first-half 2026 net loss narrowed 15% year-on-year to EUR 1.53 million, with no revenue.
- Cash fell 15% year-on-year to EUR 2.48 million at June 30, with funding expected to last through first-half 2027.
- The NFL-102 phase 2 TONIC trial targets initial enrollment in November 2026, with part A results expected in April 2027.
- Partner searches continue to fund TONIC’s part B and NFL-101’s phase 3 development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
Crypto prices
More
